In addition, previous therapies resulted in significant anemia management costs per patient. 1Ī recent analysis, 'Health Care Resources Utilization in Hepatitis C Virus Infection and Cost Associated with Adverse Events: An Analysis of the Quebec Provincial Drug Reimbursement Program Database', noted that treatment with previous therapies resulted in lower treatment completion and cure rates than treatment with Sovaldi. In addition, INESSS stated that Sovaldi fulfills a significant healthcare need in the treatment of genotype 4, as until now, only a combination of pegylated interferon and ribavirin had been used. INESSS reported several advantages of Sovaldi, including its short treatment duration (12 weeks), positive side effect profile (anemia and rashes), and administration of one pill once a day (with pegylated interferon and ribavirin) without the need for a specific diet. The listing follows a Priority Review and evaluation by the Institut national d'excellence en santé et en services sociaux (INESSS) that concluded Sovaldi provides therapeutic and clinical value, is cost effective, is well tolerated, and offers important societal benefits for the broader population. With this listing, Quebec becomes the first Canadian province to provide access to Sovaldi for treatment-naïve patients with genotypes 1 and 4 HCV infection regardless of liver severity. is pleased to announce that the Health and Social Services Ministry has placed Sovaldi ® (sofosbuvir), the newest treatment for chronic hepatitis C virus (HCV) infection approved for sale in Canada, on the Liste de médicaments (effective June 2, 2014).

MISSISSAUGA, ON, J/CNW/ - Gilead Sciences Canada, Inc. ~ Priority Review by INESSS Provides Recommendation to Treat Patients with Genotypes 1 and 4 HCV Infection Regardless of Fibrosis Level ~

Sovaldi side effect